Clinical Core

帕金森病(PD)是一种复杂的运动、认知和行为障碍， 随着时间的推移而改变。研究帕金森病的方法也变得更加复杂，包括对帕金森病的研究 生物标志物、遗传学和死后依赖神经生物学。因此，一个成功的临床核心必须 不仅描述了帕金森病受试者随时间的运动、认知和行为功能，而且 同时在同一时间段内仔细收集生物体液，并进行尸检 来自这些具有良好特征的主题的材料。临床核心的主要目标将是支持 太平洋西北Udall中心(PANUC)通过PD的纵向特征进行项目 受试者和来自这些受试者的生物样本的生成。为了实现这一目标，有两个PD 将建立受试者样本。“社区”样本(CS)将是一个更大的样本，由 临床核心研究人员在当地运动障碍诊所，或在家中，在五年中两次 年中心资金周期。这一样本将产生大量的血液样本，具有临床意义 生物标记物和基因项目所需的表征。政务司司长也将是 受试者为“年度”样本(AS)。AS将是为临床选择的较小受试者样本 筛查的特点(例如，认知亚型，如无痴呆症的认知障碍)。 因为受试者将每年在研究地点接受评估，并将有更详细的临床 人物刻画。此外，这些受试者将被招募进行腰椎穿刺术，以提供脑脊液 生物标记物研究和尸检。因此，临床核心将开发PD受试者样本， 详细的临床特征，并从受试者那里收集生物样本，以支持项目2 3例在PANUC以及密切相关的研究中。临床数据、DNA和控制组的生物体液 个人将通过相同的协议在每个地点各自由NIH资助的AD中心获得。 这些来自纵向评估的PD受试者的独特和集成的数据和样本将是 对于PANUC调查人员未来的研究以及来自内部的其他调查人员来说，这是非常宝贵的资源 以及参与机构之外的。 相关性(请参阅说明)： 帕金森氏病(PD)是一种进行性大脑疾病，目前影响着100多万人 美国人。我们现在知道，除了通常与帕金森病有关的运动问题外， 这种疾病最终还会影响一个人的思维或认知能力。这项研究将改善我们的 了解是什么导致帕金森病相关的认知能力下降，长期目标是 为帕金森病的这一致残性方面开发更好的治疗方法。

Parkinson disease (PD) is a complex disorder with motor, cognitive, and behavioral dysfunctions that change over time. The methods to study PD have also become ijiore complex, including the study of biomarkers, genetics, and postmortem-dependent neurobiology. Thus, a successful Clinical Core must not only characterize the motor, cognitive, and behavioral function in PD subjects over time, but also concomitantly carefully collect biological fluids during that same timeframe, and obtain postmortem material from these well-characterized subjects. The primary goal of the Clinical Core will be to support the Pacific Northwest Udall Center (PANUC) Projects through longitudinal characterization of PD subjects and generation of biologic samples from these subjects. To accomplish this goal two PD subject samples will be established. The "community" sample (CS) will be a larger sample evaluated by Clinical Core study personnel at local movement disorder clinics, or at their homes, twice during the five year Center funding cycle. This sample will generate the large number of blood samples, with clinical characterization, needed for the biomarker and genetic projects. The CS will also be the source of subjects for the "annual" sample (AS). The AS will be a smaller subject sample selected for clinical characteristics on screening (e.g., cognitive subtypes such as cognitive impairment without dementia). AS subjects will be evaluated annually at the study site and will have more detailed clinical characterization. In addition, these subjects will be recruited for lumbar punctures to supply CSF for biomarker studies, and for autopsy. The Clinical Core will, therefore, develop PD subject samples with detailed clinical characterization, and collect biological samples from the subjects, to support Projects 2 and 3 in PANUC as well as closely aligned studies. Clinical data, DNA, and biofluids from control individuals will be obtained through the same protocols at each sites' respective NIH-funded AD Center. These unique and integrated data and samples from longitudinally evaluated PD subjects will be an invaluable resource for future studies by PANUC investigators, and for other investigators from within and outside the participating institutions. RELEVANCE (See instructions): Parkinson's Disease (PD) is a progressive disease of the brain that currently affects over a million Americans. We now know that in addition to the movement problems commonly associated with PD this disease eventually also affects a persons thinking or cognitive abilities. This study will improve our understanding of what causes PD-associated cognitive decline, with the long-term objective of developing better treatments for this disabling facet of PD.